What is MicroBiotiX?
MicroBiotiX operates at the intersection of biotechnology and precision medicine, specializing in the development of bacteriophage and microbiome-based therapeutics. By leveraging a comprehensive library of bacteriophages curated over 15 years, the company targets high-acuity pathogens such as Pseudomonas aeruginosa and Klebsiella pneumoniae. Beyond its research capabilities, the organization maintains a high-quality GMP facility, ensuring that its therapeutic candidates meet rigorous regulatory standards for clinical application. This infrastructure is critical for the company's mission to provide viable treatment alternatives for patients suffering from multidrug-resistant bacterial infections and various autoimmune conditions.
How much funding has MicroBiotiX raised?
MicroBiotiX has raised a total of $14.3M across 1 funding round:
Series B
$14.3M
Series B (2025): $14.3M, investors not publicly disclosed
Key Investors in MicroBiotiX
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for MicroBiotiX?
Following this major enterprise-level funding, MicroBiotiX is expected to prioritize the expansion of its clinical trial programs and the optimization of its manufacturing processes. The capital will likely be deployed to scale production within its GMP-compliant facilities, facilitating the transition of lead candidates from the laboratory to human clinical studies. As the firm matures, strategic focus will shift toward regulatory milestones and potential partnerships with healthcare providers, aiming to integrate their novel therapeutics into standard care protocols for intractable infections. The company remains committed to advancing its pipeline to address the growing global threat of antimicrobial resistance.
See full MicroBiotiX company page
